---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-036843"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:13:37.016033+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vanda Q2 net loss widens to $27.2M; Fanapt sales up 27% to $29.3M

## Summary
- Fanapt net product sales $29.3M (+27% YoY); HETLIOZ $16.2M (-13%), PONVORY $7.1M (-18%).
- Net loss $27.2M (diluted EPS -$0.46) vs. net loss $4.5M (-$0.08) in Q2 2024.
- Cash $325.6M, down $15.4M from Q1 2025; full-year revenue guidance reaffirmed $210-250M.
- Regulatory milestones: Bysanti NDA PDUFA Feb 21, 2026; Tradipitant NDA PDUFA Dec 30, 2025; Imsidolimab BLA submission expected 2025.

## SEC filing metadata
- accession: 0001628280-25-036843
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828025036843/0001628280-25-036843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828025036843/vnda-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-036843
- JSON: https://secwatch.observer/filing/0001628280-25-036843.json
- Plain text: https://secwatch.observer/filing/0001628280-25-036843.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.